Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | AGXT | P21549 | 2/20 | 0.38 |
| ▸ | MPO | P05164 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | COMT | P21964 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19157479 | 0.84 | THRB (0.44) | IDO1AGXTMPOLMNATP53 | |
| SCHEMBL19220570 | 0.79 | MPO (0.35) | IDO1AGXTMPOLMNAPTGS2 | |
| SCHEMBL19157898 | 0.76 | IDO1 (0.42) | IDO1AGXTMPOLMNANPC1 | |
| SCHEMBL19225308 | 0.72 | GPER1 (0.41) | IDO1AGXTMPOPTGS2F2RL3 | |
| SCHEMBL20724163 | 0.72 | IDO1 (0.39) | IDO1AGXTMPOPTGS2F2RL3 | |
| SCHEMBL20724156 | 0.72 | MPO (0.38) | MPOLMNACOMTTP53MAPT | |
| SCHEMBL19158098 | 0.70 | GRM4 (0.36) | IDO1AGXTMPOCOMTTP53 | |
| SCHEMBL16016319 | 0.70 | NPC1 (0.46) | IDO1AGXTMPOPTGS2PTGS1 | |
| SCHEMBL19225188 | 0.70 | SLC5A2 (0.42) | IDO1AGXTMPOPTGS2GAA | |
| SCHEMBL16016321 | 0.69 | IDO1 (0.41) | IDO1AGXTMPOPTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202404-B2 | Polycyclic pyridone derivative having integrase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2019-02-12 | — | — | US | disclosed |
| US-10011613-B2 | Polycyclic pyridone derivative having integrase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2018-07-03 | — | — | US | disclosed |
| US-20170226128-A1 | POLYCYCLIC PYRIDONE DERIVATIVE HAVING INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10011613-B2 | Polycyclic pyridone derivative having integrase inhibitory activity | TYMP, CDK6, IMPA1 | IDO1 138/4885AGXT 2646/4885MPO 4689/4885 |
| US-20170226128-A1 | POLYCYCLIC PYRIDONE DERIVATIVE HAVING INTEGRASE INHIBITORY ACTIVITY | TYMP, CDK6, IMPA1 | IDO1 138/4885AGXT 2646/4885MPO 4689/4885 |
| US-10202404-B2 | Polycyclic pyridone derivative having integrase inhibitory activity | TYMP, CDK6, IMPA1 | IDO1 138/4885AGXT 2646/4885MPO 4689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.